分享产品介绍 评论(0)
物种
Human分子别名
Fibroblast growth factor 23, FGF-23, Phosphatonin, Tumor-derived hypophosphatemia-inducing factorAccession
Q9GZV9表达序列
Tyr25-Val251(R179Q)
表达宿主
HEK293分子量
26-34 kDa (Reducing)
纯度
>95% by SDS-PAGE & HPLC.内毒素含量
<0.1EU/μg活性
EC50 = 0.12-0.25 μg/ml标记
Unconjugated标签
No Tag性状
Lyophilized powder缓冲体系
10mM NaAc, 0.1M L-Arg, pH6.0
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
Nat Rev Nephrol. 2023;19:185‑193.
Metabolism. 2020;103:153865.
FGF23 is predominantly secreted by osteocytes, with its secretion and cleavage tightly regulated by serum phosphate, 1,25-dihydroxyvitamin D (1,25D), and parathyroid hormone (PTH). It binds to FGF receptors in concert with the obligate co‑receptor α‑Klotho to promote phosphaturia and suppress renal 1,25D synthesis, thereby controlling systemic phosphorus balance. Disorders of FGF23 signaling lead to either hypophosphatemia (e.g., X-linked hypophosphatemia, XLH) or hyperphosphatemia (e.g., familial tumoral calcinosis).
生物活性
Determined by its ability to stimulate the proliferation of murine NIH-3T3 cells. The expected EC50 for this effect is 0.12-0.25 μg/ml, in the presence of murine Klotho and heparin.
电泳
2μg (R: reducing condition, N: non-reducing condition).
反相高效液相色谱(RP-HPLC)
>95% as determined by RP-HPLC.
评论(0)